Breast Cancer Proteomics and Molecular Heterogeneity
This is a translational study. Patient will undergo standard treatment and tissue and blood
samples will be taken at various time points:
Tissue: Fresh frozen (FF) and Formalin fixed paraffin embedded tissue (FFPE) will be
collected at time of surgery/biopsy of a primary or a recurrent/metastatic tumour tissue.
Blood: Two types of study bloods (non-heparinised and Ethylenediaminetetraacetic acid
(EDTA)) will be taken pre-neoadjuvant treatment (if applicable), pre- and post-operatively
of primary and recurrent/ metastatic breast cancer (if recurrent/metastatic diagnosis and no
biopsy/surgery required then study bloods will be taken prior to starting treatment).
Additional blood samples will be taken annually at follow-up visits for 5 years from primary
cases and for up to 2 years from recurrent/metastatic cases.
Non-heparinised blood will be processed to serum. Clinical data will be collected at all
times of biological sampling.
Observational Model: Cohort
Investigation of proteins and their pathways in primary breast cancer
Investigation of proteins and their pathways in primary breast cancer, which are associated with patient outcome.
Ireland: Health Information and Quality Authority